Barclays analyst Luke Sergott downgraded Syneos Health to Underweight from Overweight with a $25 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYNH:
- Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
- Syneos Health partners with Fosun Pharma USA to launch serplulimab
- Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023
- Syneos Health backs FY22 EPS view $4.69-$4.87, consensus $4.70
- Syneos Health CFO Jason Meggs to transition out of role